A notable pharmaceutical company in India faced significant challenges in overseeing its complex IT infrastructure. Obsolete legacy systems, inconsistent data sources, and the need to comply with strict regulatory requirements hampered innovation.
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced that Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, has been approved by the US Food and Drug...
India's HempStreet and the first Ayurvedic cannabis research retail company have raised $1 million in a pre-A round. The round was led by their current investor,
Swedish pharmaceutical company Orexo AB (publ.) announces that the US Food and Drug Administration (FDA) have approved
As per industry analysts, India's pharmaceutical business might surpass USD 130 billion by 2030, owing to rising market potential and increased demand in international markets. They stated that the company's revenue for the fiscal year 2022-23 was...
Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company reinventing brain medication research, announced the start of a phase 1 single ascending dose/multiple ascending dosage trial in healthy adult volunteers to evaluate...
IRCAD India, a mirror institute of IRCAD France (Strasbourg), has recently been established in collaboration with the Sri Aurobindo Institute of Medical Sciences (SAIMS), Indore, India
Sami-Sabinsa Group Limited, a research-focused global health science company,has signed a mutual agreement with O2 Renewable Energy VIII Private Limited to establish a total installed capacity of 240 MW(100 MW of wind and 140 MW AC of solar) for...
Cadila Pharmaceuticals, located in Ahmedabad, has opened its state-of-the-art Active Pharmaceutical Ingredients (API) Plant in Dahej, Bharuch district. The Rs 200 crore facility is outfitted with the latest Distributed Control System (DCS)...
MC2 Therapeutics announced the enrollment of the first patients in a phase 2 proof-of-concept trial evaluating the safety and efficacy of MC2-25 VLS, an innovative new drug candidate for the treatment of urea-associated skin diseases, including...
, CDSCO.jpg)
